Showing 1765 results
-
Press release /74% of patients in MEASURE 2 achieved clinically significant and sustained improvement in symptoms of ankylosing spondylitis (AS) with secukinumab 150 mg after one year of treatment[1] AS is…
-
Press release /Unique Cosentyx® (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis[1]-[4] Cosentyx results represent the first data…
-
Press release /EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily…
-
Press release /New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before…
-
Story /More than 100,000 patients with heart failure in China are using our new AI-enabled platform, AI Nurse, to manage their condition and aim for better health.
-
Story /Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.